Back to top

immuno-therapy: Archive

Zacks Equity Research

CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal

Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate cancer.

BMYNegative Net Change PFENegative Net Change GILDNegative Net Change CADLNegative Net Change